vs
Alight, Inc.（ALIT）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
Alight, Inc.的季度营收约是ICU MEDICAL INC的1.2倍（$653.0M vs $540.7M），ICU MEDICAL INC净利率更高（-2.9% vs -142.7%，领先139.8%），Alight, Inc.同比增速更快（-4.0% vs -14.1%），Alight, Inc.自由现金流更多（$99.0M vs $36.0M），过去两年Alight, Inc.的营收复合增速更高（8.1% vs -2.3%）
Alight公司是一家美国信息技术与咨询企业，专注于人力资源相关业务，主打基于云的系统服务、业务外包与咨询服务，为大型企业提供人力资本管理平台与外包方案，业务范围涵盖健康福利管理、财务管理以及退休规划等领域。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
ALIT vs ICUI — 直观对比
营收规模更大
ALIT
是对方的1.2倍
$540.7M
营收增速更快
ALIT
高出10.2%
-14.1%
净利率更高
ICUI
高出139.8%
-142.7%
自由现金流更多
ALIT
多$63.0M
$36.0M
两年增速更快
ALIT
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $653.0M | $540.7M |
| 净利润 | $-932.0M | $-15.7M |
| 毛利率 | 36.8% | 37.5% |
| 营业利润率 | -114.9% | 1.0% |
| 净利率 | -142.7% | -2.9% |
| 营收同比 | -4.0% | -14.1% |
| 净利润同比 | -11750.0% | 34.0% |
| 每股收益（稀释后） | $-1.77 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALITICUI
| Q4 25 | $653.0M | $540.7M | ||
| Q3 25 | $533.0M | $537.0M | ||
| Q2 25 | $528.0M | $548.9M | ||
| Q1 25 | $548.0M | $604.7M | ||
| Q4 24 | $680.0M | $629.8M | ||
| Q3 24 | $555.0M | $589.1M | ||
| Q2 24 | $538.0M | $596.5M | ||
| Q1 24 | $559.0M | $566.7M |
净利润ALITICUI
| Q4 25 | $-932.0M | $-15.7M | ||
| Q3 25 | $-1.1B | $-3.4M | ||
| Q2 25 | $-1.1B | $35.3M | ||
| Q1 25 | $-25.0M | $-15.5M | ||
| Q4 24 | $8.0M | $-23.8M | ||
| Q3 24 | $-74.0M | $-33.0M | ||
| Q2 24 | $23.0M | $-21.4M | ||
| Q1 24 | $-114.0M | $-39.5M |
毛利率ALITICUI
| Q4 25 | 36.8% | 37.5% | ||
| Q3 25 | 33.4% | 37.4% | ||
| Q2 25 | 33.3% | 37.9% | ||
| Q1 25 | 31.2% | 34.7% | ||
| Q4 24 | 39.9% | 36.1% | ||
| Q3 24 | 31.4% | 34.8% | ||
| Q2 24 | 31.0% | 34.8% | ||
| Q1 24 | 32.6% | 32.7% |
营业利润率ALITICUI
| Q4 25 | -114.9% | 1.0% | ||
| Q3 25 | -248.0% | 2.6% | ||
| Q2 25 | -191.3% | 1.9% | ||
| Q1 25 | -1.5% | 2.1% | ||
| Q4 24 | 6.5% | 6.0% | ||
| Q3 24 | -7.6% | 1.4% | ||
| Q2 24 | -9.7% | 1.3% | ||
| Q1 24 | -7.2% | -1.9% |
净利率ALITICUI
| Q4 25 | -142.7% | -2.9% | ||
| Q3 25 | -200.2% | -0.6% | ||
| Q2 25 | -203.2% | 6.4% | ||
| Q1 25 | -4.6% | -2.6% | ||
| Q4 24 | 1.2% | -3.8% | ||
| Q3 24 | -13.3% | -5.6% | ||
| Q2 24 | 4.3% | -3.6% | ||
| Q1 24 | -20.4% | -7.0% |
每股收益（稀释后）ALITICUI
| Q4 25 | $-1.77 | $-0.63 | ||
| Q3 25 | $-2.02 | $-0.14 | ||
| Q2 25 | $-2.03 | $1.43 | ||
| Q1 25 | $-0.05 | $-0.63 | ||
| Q4 24 | $0.02 | $-0.97 | ||
| Q3 24 | $-0.14 | $-1.35 | ||
| Q2 24 | $0.04 | $-0.88 | ||
| Q1 24 | $-0.21 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $273.0M | — |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $1.0B | $2.1B |
| 总资产 | $4.6B | $4.1B |
| 负债/权益比越低杠杆越低 | 1.92× | — |
8季度趋势，按日历期对齐
现金及短期投资ALITICUI
| Q4 25 | $273.0M | — | ||
| Q3 25 | $205.0M | — | ||
| Q2 25 | $227.0M | — | ||
| Q1 25 | $223.0M | — | ||
| Q4 24 | $343.0M | $308.6M | ||
| Q3 24 | $300.0M | $312.5M | ||
| Q2 24 | $183.0M | $302.6M | ||
| Q1 24 | $256.0M | $251.4M |
总债务ALITICUI
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $2.8B | — |
股东权益ALITICUI
| Q4 25 | $1.0B | $2.1B | ||
| Q3 25 | $2.0B | $2.1B | ||
| Q2 25 | $3.1B | $2.1B | ||
| Q1 25 | $4.2B | $2.0B | ||
| Q4 24 | $4.3B | $2.0B | ||
| Q3 24 | $4.3B | $2.0B | ||
| Q2 24 | $4.5B | $2.0B | ||
| Q1 24 | $4.5B | $2.1B |
总资产ALITICUI
| Q4 25 | $4.6B | $4.1B | ||
| Q3 25 | $5.5B | $4.1B | ||
| Q2 25 | $6.8B | $4.1B | ||
| Q1 25 | $7.9B | $4.2B | ||
| Q4 24 | $8.2B | $4.2B | ||
| Q3 24 | $8.3B | $4.3B | ||
| Q2 24 | $10.5B | $4.3B | ||
| Q1 24 | $10.7B | $4.3B |
负债/权益比ALITICUI
| Q4 25 | 1.92× | — | ||
| Q3 25 | 1.00× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.62× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $124.0M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $99.0M | $36.0M |
| 自由现金流率自由现金流/营收 | 15.2% | 6.6% |
| 资本支出强度资本支出/营收 | 3.8% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $250.0M | $91.8M |
8季度趋势，按日历期对齐
经营现金流ALITICUI
| Q4 25 | $124.0M | $60.6M | ||
| Q3 25 | $77.0M | $56.7M | ||
| Q2 25 | $86.0M | $11.2M | ||
| Q1 25 | $73.0M | $51.3M | ||
| Q4 24 | $118.0M | $40.2M | ||
| Q3 24 | $-24.0M | $36.1M | ||
| Q2 24 | $58.0M | $82.0M | ||
| Q1 24 | $100.0M | $45.8M |
自由现金流ALITICUI
| Q4 25 | $99.0M | $36.0M | ||
| Q3 25 | $49.0M | $27.6M | ||
| Q2 25 | $58.0M | $-8.5M | ||
| Q1 25 | $44.0M | $36.7M | ||
| Q4 24 | $92.0M | $16.1M | ||
| Q3 24 | $-52.0M | $16.2M | ||
| Q2 24 | $22.0M | $62.5M | ||
| Q1 24 | $69.0M | $29.9M |
自由现金流率ALITICUI
| Q4 25 | 15.2% | 6.6% | ||
| Q3 25 | 9.2% | 5.1% | ||
| Q2 25 | 11.0% | -1.5% | ||
| Q1 25 | 8.0% | 6.1% | ||
| Q4 24 | 13.5% | 2.6% | ||
| Q3 24 | -9.4% | 2.7% | ||
| Q2 24 | 4.1% | 10.5% | ||
| Q1 24 | 12.3% | 5.3% |
资本支出强度ALITICUI
| Q4 25 | 3.8% | 4.6% | ||
| Q3 25 | 5.3% | 5.4% | ||
| Q2 25 | 5.3% | 3.6% | ||
| Q1 25 | 5.3% | 2.4% | ||
| Q4 24 | 3.8% | 3.8% | ||
| Q3 24 | 5.0% | 3.4% | ||
| Q2 24 | 6.7% | 3.3% | ||
| Q1 24 | 5.5% | 2.8% |
现金转化率ALITICUI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | 14.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.52× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALIT
| Recurring | $607.0M | 93% |
| Projects | $46.0M | 7% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
